Biovica International AB (publ) (BIOVIC-B.ST)
Biovica International AB (publ) operates in the Biotechnology industry of the Healthcare sector, headquartered in Uppsala, UP, SE. The stock last traded at $0.31, up 0.32% on the session, giving a market capitalisation of $87.1M. Its beta of 1.15 implies it has historically moved more than the broad market.
Biovica International AB (publ) operates as a biotechnology enterprise, concentrating on the development and market introduction of sophisticated blood-based biomarker tests. These diagnostic solutions aim to enhance the tracking and prediction of cancer treatment efficacy across Sweden and globally, with a significant focus on breast cancer. A key offering is DiviTum, a biomarker assay engineered to measure the activity levels of the enzyme thymidine kinase-1 within blood serum or cell cultures. The company's clientele includes oncology research centers, pharmaceutical corporations, and various collaborative organizations. Established in 2008, Biovica's main office is situated in Uppsala, Sweden.
Biovica International AB (publ) is most often compared with the following Healthcare names: